Immuno-Oncology Outlook: PD-1 Data Emerges In Cervical Cancer

Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.

Growth
new immunotherapy options are emerging in the cervical cancer pipeline • Source: Shutterstock

Cancer of the uterine cervix, or cervical cancer, is the second most common form of cancer among women worldwide, with approximately 500,000 new cases reported each year.

However, while the pipeline for vaccines aimed at preventing the disease is vast, treatment options are limited

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

More from Anticancer